抄録
An overview is presented of vanadium-based insulinomimetic and anti-diabetic complexes aiming at the development of clinically useful anti-diabetic medicines as replacements of daily insulin injections for type 1 diabetes and synthetic antidiabetic drugs. After described on the advantage for the use of vanadyl ion (oxovanadium(IV), +4 oxidation state of vanadium, VO2+) in terms of toxicity in animals and bio-state of the metal ion, recent progress on the development of antidiabetic vanadyl complexes proposed in our research group is reviewed with emphasis of the importance of the study on structure-activity relationship for vanadyl-picolinate complexes to find more active complexes than the leading compound and of the development of new drug delivery system either the enteric-coated capsule containing simple vanadyl sulfate or the use of a biopolymer, poly(γ-glutamic) acid, bound with vanadyl sulfate. The challenges for future research are also described.
